A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Aldesleukin (Primary) ; Aflibercept
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 05 Apr 2017 Primary endpoint (Progression-free survival ) has been met.